USPTO serial 79423184
VISYNC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 18, 2026
- Examiner
- OH, HYUN-JUNG
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with VISYNC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
R. Peter Spies
R. Peter Spies DTL, Ltd160 N Wacker DriveSuite 500Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals, medical and veterinary preparations all of the foregoing for the prevention, diagnosis, treatment and improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals; biopharmaceutical preparations for the treatment of inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders and advanced therapy medicinal products, namely, gene therapy medicinal products in the nature of virus or virus-like particles used for medical purposes or in the nature of genetically engineered tissues for transplant purposes, somatic cell therapy medicinal products in the nature of antibody reagents used for the detection of antigens in cells for medical purposes, tissue engineered products in the nature of genetically engineered tissues for transplant purposes, and combined advanced therapy medicinal products; medicines for human use that are based on genes, tissues or cells for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management; drugs for medical purposes, namely, pharmaceutical preparations for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management; pharmaceutical preparations for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management; biopharmaceutical preparations for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management and advanced therapy medicinal products for systemic or targeted delivery, namely, nasal spray preparations suitable for nasal delivery, nose-to-brain delivery for medical purposes; advanced therapy medicinal products, namely, gene therapy medicinal products in the nature of virus or virus-like particles used for medical purposes or in the nature of genetically engineered tissues for transplant purposes, somatic cell therapy medicinal products in the nature of antibody reagents used for the detection of antigens in cells for medical purposes, tissue engineered products in the nature of genetically engineered tissues for transplant purposes, and combined advanced therapy medicinal products, medical and veterinary preparations, namely, medical and veterinary preparations comprising biomolecules, cells, viruses, virus-like particles, exosomes, nanoparticles or liposomes for the prevention, diagnosis, treatment of or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management; vaccines; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic reagents and kits consisting primarily of probes, buffers and reagents for use in microbial testing. | ACTIVE | — |
| 010 | Surgical, medical and veterinary apparatus and instruments for medical, dental or veterinary use; medical apparatus and instruments, namely, drug delivery devices, sold empty, in the nature of syringes, infusion sets, inhalers and diagnostic apparatus for medical purposes used in medical laboratories for testing blood sugar levels, cancer cells, DNA; diagnostic, examination and monitoring equipment in the nature of imaging equipment, microscopes, blood analysers being haematology analysers for medical diagnostic uses, biochemistry analysers, immunoassay analysers, microbiology incubators, centrifuges | ACTIVE | — |
| 042 | Scientific and technological consulting services in the pharmaceutical industry and research and design relating thereto; industrial analysis in the nature of product testing, industrial research and industrial design services in the field of pharmaceutical, veterinary and medical goods; quality control of services for others and providing user authentication services using single sign-on technology for online software applications; pharmaceutical and biological analysis and research services; medical research relating to the research, development and manufacturing activities in the field of medicines, namely biomolecules, cells, viruses, virus-like particles, exosomes, nanoparticles, liposomes and vaccines; medical research relating to the research, development and manufacturing activities in the field of delivery of medicines namely, nasal spray preparations suitable for nasal delivery, nose-to-brain delivery; technological research being research and development of manufacturing processes for the pharmaceutical industry; optimization of processes in the nature of technological consultancy services for search engine optimization for the pharmaceutical industry; design and development of medical diagnostic apparatus for detecting inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders; scientific research for medical purposes in the area of inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders. | ACTIVE | — |
| 044 | Medical diagnostic services; handling of blood samples in the nature of blood testing being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; performing diagnosis of diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by VISYNC TECHNOLOGIES, S.A.
- Other trademarks owned by VISYNC TECHNOLOGIES, S.A.
- Other trademarks owned by VISYNC TECHNOLOGIES, S.A.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named VISYNC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 15, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 7, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 7, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 3, 2026 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Aug 18, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 18, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 17, 2026 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jun 30, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 30, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 24, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 4, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 3, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 3, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 3, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 21, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 21, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 21, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 28, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 28, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 28, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 16, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 28, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 28, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 5, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 4, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 30, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| May 9, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 9, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 8, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |